Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Epithelial-to-mesenchymal transition signature assessment in colorectal cancer quantifies tumour stromal content rather than true transition.

McCorry AMB, Loughrey MB, Longley DB, Lawler M, Dunne PD.

J Pathol. 2018 Aug 13. doi: 10.1002/path.5155. [Epub ahead of print]

PMID:
30105762
2.

Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy.

Allen WL, Dunne PD, McDade S, Scanlon E, Loughrey M, Coleman H, McCann C, McLaughlin K, Nemeth Z, Syed N, Jithesh P, Arthur K, Wilson R, Coyle V, McArt D, Murray GI, Samuel L, Nuciforo P, Jimenez J, Argiles G, Dienstmann R, Tabernero J, Messerini L, Nobili S, Mini E, Sheahan K, Ryan E, Johnston PG, Van Schaeybroeck S, Lawler M, Longley DB.

JCO Precis Oncol. 2018 Jun 13;2018. doi: 10.1200/PO.17.00241.

3.

FLIP as a therapeutic target in cancer.

Humphreys L, Espona-Fiedler M, Longley DB.

FEBS J. 2018 May 28. doi: 10.1111/febs.14523. [Epub ahead of print] Review.

PMID:
29806737
4.

Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer.

Dunne PD, Coleman HG, Bankhead P, Alderdice M, Gray RT, McQuaid S, Bingham V, Loughrey MB, James JA, McCorry AMB, Gilmore A, Holohan C, Klingbiel D, Tejpar S, Johnston PG, McArt DG, Di Nicolantonio F, Longley DB, Lawler M.

Oncotarget. 2018 Feb 13;9(17):13834-13847. doi: 10.18632/oncotarget.24481. eCollection 2018 Mar 2.

5.

Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711.

Crawford N, Salvucci M, Hellwig CT, Lincoln FA, Mooney RE, O'Connor CL, Prehn JH, Longley DB, Rehm M.

Cell Death Differ. 2018 Mar 2. doi: 10.1038/s41418-018-0082-y. [Epub ahead of print]

6.

IHC-based subcellular quantification provides new insights into prognostic relevance of FLIP and procaspase-8 in non-small-cell lung cancer.

Hutchinson RA, Coleman HG, Gately K, Young V, Nicholson S, Cummins R, Kay E, Hynes SO, Dunne PD, Senevirathne S, Hamilton PW, McArt DG, Longley DB.

Cell Death Discov. 2017 Aug 14;3:17050. doi: 10.1038/cddiscovery.2017.50. eCollection 2017.

7.

Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification.

Dunne PD, Alderdice M, O'Reilly PG, Roddy AC, McCorry AMB, Richman S, Maughan T, McDade SS, Johnston PG, Longley DB, Kay E, McArt DG, Lawler M.

Nat Commun. 2017 May 31;8:15657. doi: 10.1038/ncomms15657.

8.

A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer.

Salvucci M, Würstle ML, Morgan C, Curry S, Cremona M, Lindner AU, Bacon O, Resler AJ, Murphy ÁC, O'Byrne R, Flanagan L, Dasgupta S, Rice N, Pilati C, Zink E, Schöller LM, Toomey S, Lawler M, Johnston PG, Wilson R, Camilleri-Broët S, Salto-Tellez M, McNamara DA, Kay EW, Laurent-Puig P, Van Schaeybroeck S, Hennessy BT, Longley DB, Rehm M, Prehn JH.

Clin Cancer Res. 2017 Mar 1;23(5):1200-1212. doi: 10.1158/1078-0432.CCR-16-1084. Epub 2016 Sep 20.

9.

FLIP: A Targetable Mediator of Resistance to Radiation in Non-Small Cell Lung Cancer.

McLaughlin KA, Nemeth Z, Bradley CA, Humphreys L, Stasik I, Fenning C, Majkut J, Higgins C, Crawford N, Holohan C, Johnston PG, Harrison T, Hanna GG, Butterworth KT, Prise KM, Longley DB.

Mol Cancer Ther. 2016 Oct;15(10):2432-2441. Epub 2016 Jul 29.

10.

Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy.

Dunne PD, McArt DG, O'Reilly PG, Coleman HG, Allen WL, Loughrey M, Van Schaeybroeck S, McDade S, Salto-Tellez M, Longley DB, Lawler M, Johnston PG.

Cancer Immunol Res. 2016 Jul;4(7):582-91. doi: 10.1158/2326-6066.CIR-15-0302. Epub 2016 May 13.

11.

Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer.

Dunne PD, O'Reilly PG, Coleman HG, Gray RT, Longley DB, Johnston PG, Salto-Tellez M, Lawler M, McArt DG.

Oncotarget. 2016 Jun 14;7(24):36632-36644. doi: 10.18632/oncotarget.9126.

12.

Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer.

Dunne PD, McArt DG, Bradley CA, O'Reilly PG, Barrett HL, Cummins R, O'Grady T, Arthur K, Loughrey MB, Allen WL, McDade SS, Waugh DJ, Hamilton PW, Longley DB, Kay EW, Johnston PG, Lawler M, Salto-Tellez M, Van Schaeybroeck S.

Clin Cancer Res. 2016 Aug 15;22(16):4095-104. doi: 10.1158/1078-0432.CCR-16-0032. Epub 2016 May 5.

13.

PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy.

Armstrong CW, Maxwell PJ, Ong CW, Redmond KM, McCann C, Neisen J, Ward GA, Chessari G, Johnson C, Crawford NT, LaBonte MJ, Prise KM, Robson T, Salto-Tellez M, Longley DB, Waugh DJ.

Oncotarget. 2016 Feb 16;7(7):7885-98. doi: 10.18632/oncotarget.6955.

14.

DED or alive: assembly and regulation of the death effector domain complexes.

Riley JS, Malik A, Holohan C, Longley DB.

Cell Death Dis. 2015 Aug 27;6:e1866. doi: 10.1038/cddis.2015.213. Review.

15.

HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL.

Carson R, Celtikci B, Fenning C, Javadi A, Crawford N, Carbonell LP, Lawler M, Longley DB, Johnston PG, Van Schaeybroeck S.

Clin Cancer Res. 2015 Jul 15;21(14):3230-3240. doi: 10.1158/1078-0432.CCR-14-2701. Epub 2015 Mar 26.

16.

Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity.

Schmid D, Jarvis GE, Fay F, Small DM, Greene MK, Majkut J, Spence S, McLaughlin KM, McCloskey KD, Johnston PG, Kissenpfennig A, Longley DB, Scott CJ.

Cell Death Dis. 2014 Oct 9;5:e1454. doi: 10.1038/cddis.2014.413.

17.

Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine.

Schmid D, Fay F, Small DM, Jaworski J, Riley JS, Tegazzini D, Fenning C, Jones DS, Johnston PG, Longley DB, Scott CJ.

Mol Ther. 2014 Dec;22(12):2083-92. doi: 10.1038/mt.2014.137. Epub 2014 Jul 23.

18.

ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer.

Van Schaeybroeck S, Kalimutho M, Dunne PD, Carson R, Allen W, Jithesh PV, Redmond KL, Sasazuki T, Shirasawa S, Blayney J, Michieli P, Fenning C, Lenz HJ, Lawler M, Longley DB, Johnston PG.

Cell Rep. 2014 Jun 26;7(6):1940-55. doi: 10.1016/j.celrep.2014.05.032. Epub 2014 Jun 12.

19.

Differential affinity of FLIP and procaspase 8 for FADD's DED binding surfaces regulates DISC assembly.

Majkut J, Sgobba M, Holohan C, Crawford N, Logan AE, Kerr E, Higgins CA, Redmond KL, Riley JS, Stasik I, Fennell DA, Van Schaeybroeck S, Haider S, Johnston PG, Haigh D, Longley DB.

Nat Commun. 2014 Feb 28;5:3350. doi: 10.1038/ncomms4350.

20.

Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.

Turkington RC, Longley DB, Allen WL, Stevenson L, McLaughlin K, Dunne PD, Blayney JK, Salto-Tellez M, Van Schaeybroeck S, Johnston PG.

Cell Death Dis. 2014 Feb 6;5:e1046. doi: 10.1038/cddis.2014.10.

21.

Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer.

Riley JS, Hutchinson R, McArt DG, Crawford N, Holohan C, Paul I, Van Schaeybroeck S, Salto-Tellez M, Johnston PG, Fennell DA, Gately K, O'Byrne K, Cummins R, Kay E, Hamilton P, Stasik I, Longley DB.

Cell Death Dis. 2013 Dec 5;4:e951. doi: 10.1038/cddis.2013.481.

22.

AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.

Dunne PD, McArt DG, Blayney JK, Kalimutho M, Greer S, Wang T, Srivastava S, Ong CW, Arthur K, Loughrey M, Redmond K, Longley DB, Salto-Tellez M, Johnston PG, Van Schaeybroeck S.

Clin Cancer Res. 2014 Jan 1;20(1):164-75. doi: 10.1158/1078-0432.CCR-13-1354. Epub 2013 Oct 29.

23.

Cancer drug resistance: an evolving paradigm.

Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG.

Nat Rev Cancer. 2013 Oct;13(10):714-26. doi: 10.1038/nrc3599. Review.

PMID:
24060863
24.

SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesothelioma.

Crawford N, Stasik I, Holohan C, Majkut J, McGrath M, Johnston PG, Chessari G, Ward GA, Waugh DJ, Fennell DA, Longley DB.

Cell Death Dis. 2013 Jul 18;4:e733. doi: 10.1038/cddis.2013.258.

25.

Enhanced antitumor activity of the photosensitizer meso-Tetra(N-methyl-4-pyridyl) porphine tetra tosylate through encapsulation in antibody-targeted chitosan/alginate nanoparticles.

Abdelghany SM, Schmid D, Deacon J, Jaworski J, Fay F, McLaughlin KM, Gormley JA, Burrows JF, Longley DB, Donnelly RF, Scott CJ.

Biomacromolecules. 2013 Feb 11;14(2):302-10. doi: 10.1021/bm301858a. Epub 2013 Jan 31.

26.

Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression.

Barbone D, Cheung P, Battula S, Busacca S, Gray SG, Longley DB, Bueno R, Sugarbaker DJ, Fennell DA, Broaddus VC.

PLoS One. 2012;7(12):e52753. doi: 10.1371/journal.pone.0052753. Epub 2012 Dec 26.

27.

Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer.

Paul I, Chacko AD, Stasik I, Busacca S, Crawford N, McCoy F, McTavish N, Wilson B, Barr M, O'Byrne KJ, Longley DB, Fennell DA.

Cell Death Dis. 2012 Dec 20;3:e449. doi: 10.1038/cddis.2012.186.

28.

Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia.

McLornan D, Hay J, McLaughlin K, Holohan C, Burnett AK, Hills RK, Johnston PG, Mills KI, McMullin MF, Longley DB, Gilkes A.

Br J Haematol. 2013 Jan;160(2):188-98. doi: 10.1111/bjh.12108. Epub 2012 Nov 20. Erratum in: Br J Haematol. 2013 Aug;162(3):428. Gilkes, Amanda [added].

PMID:
23167276
29.

Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer.

Stevenson L, Allen WL, Turkington R, Jithesh PV, Proutski I, Stewart G, Lenz HJ, Van Schaeybroeck S, Longley DB, Johnston PG.

Clin Cancer Res. 2012 Oct 1;18(19):5412-26. doi: 10.1158/1078-0432.CCR-12-1780. Epub 2012 Aug 2.

30.

Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.

Allen WL, Turkington RC, Stevenson L, Carson G, Coyle VM, Hector S, Dunne P, Van Schaeybroeck S, Longley DB, Johnston PG.

Mol Cancer Ther. 2012 Aug;11(8):1724-34. doi: 10.1158/1535-7163.MCT-12-0207. Epub 2012 Jun 4.

31.

Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy.

McCourt C, Maxwell P, Mazzucchelli R, Montironi R, Scarpelli M, Salto-Tellez M, O'Sullivan JM, Longley DB, Waugh DJ.

Clin Cancer Res. 2012 Jul 15;18(14):3822-33. doi: 10.1158/1078-0432.CCR-11-3277. Epub 2012 May 23.

32.

Constitutive and treatment-induced CXCL8-signalling selectively modulates the efficacy of anti-metabolite therapeutics in metastatic prostate cancer.

Wilson C, Maxwell PJ, Longley DB, Wilson RH, Johnston PG, Waugh DJ.

PLoS One. 2012;7(5):e36545. doi: 10.1371/journal.pone.0036545. Epub 2012 May 9.

33.

Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis.

Kerr E, Holohan C, McLaughlin KM, Majkut J, Dolan S, Redmond K, Riley J, McLaughlin K, Stasik I, Crudden M, Van Schaeybroeck S, Fenning C, O'Connor R, Kiely P, Sgobba M, Haigh D, Johnston PG, Longley DB.

Cell Death Differ. 2012 Aug;19(8):1317-27. doi: 10.1038/cdd.2012.8. Epub 2012 Feb 10.

34.

Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent.

Hurwitz JL, Stasik I, Kerr EM, Holohan C, Redmond KM, McLaughlin KM, Busacca S, Barbone D, Broaddus VC, Gray SG, O'Byrne KJ, Johnston PG, Fennell DA, Longley DB.

Eur J Cancer. 2012 May;48(7):1096-107. doi: 10.1016/j.ejca.2011.11.009. Epub 2011 Dec 10.

PMID:
22154545
35.

A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.

Allen WL, Stevenson L, Coyle VM, Jithesh PV, Proutski I, Carson G, Gordon MA, Lenz HJ, Van Schaeybroeck S, Longley DB, Johnston PG.

Mol Cancer Ther. 2012 Jan;11(1):119-31. doi: 10.1158/1535-7163.MCT-11-0510. Epub 2011 Oct 25.

36.

Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery.

Fay F, McLaughlin KM, Small DM, Fennell DA, Johnston PG, Longley DB, Scott CJ.

Biomaterials. 2011 Nov;32(33):8645-53. doi: 10.1016/j.biomaterials.2011.07.065. Epub 2011 Aug 27.

PMID:
21875750
37.

Calbindin 2 (CALB2) regulates 5-fluorouracil sensitivity in colorectal cancer by modulating the intrinsic apoptotic pathway.

Stevenson L, Allen WL, Proutski I, Stewart G, Johnston L, McCloskey K, Wilson PM, Longley DB, Johnston PG.

PLoS One. 2011;6(5):e20276. doi: 10.1371/journal.pone.0020276. Epub 2011 May 24.

38.

The colorectal cancer disease-specific transcriptome may facilitate the discovery of more biologically and clinically relevant information.

Allen WL, Jithesh PV, Oliver GR, Proutski I, Longley DB, Lenz HJ, Proutski V, Harkin P, Johnston PG.

BMC Cancer. 2010 Dec 20;10:687. doi: 10.1186/1471-2407-10-687.

39.

Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17.

Van Schaeybroeck S, Kyula JN, Fenton A, Fenning CS, Sasazuki T, Shirasawa S, Longley DB, Johnston PG.

Cancer Res. 2011 Feb 1;71(3):1071-80. doi: 10.1158/0008-5472.CAN-10-0714. Epub 2010 Dec 10.

40.

Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis.

Crawford N, Chacko AD, Savage KI, McCoy F, Redmond K, Longley DB, Fennell DA.

Apoptosis. 2011 Mar;16(3):311-20. doi: 10.1007/s10495-010-0561-1.

PMID:
21107700
41.

In vitro and in vivo characterisation of a novel c-FLIP-targeted antisense phosphorothioate oligonucleotide.

Logan AE, Wilson TR, Fenning C, Cummins R, Kay E, Johnston PG, Longley DB.

Apoptosis. 2010 Dec;15(12):1435-43. doi: 10.1007/s10495-010-0533-5.

PMID:
20683665
42.

Voltage dependent anion channel-1 regulates death receptor mediated apoptosis by enabling cleavage of caspase-8.

Chacko AD, Liberante F, Paul I, Longley DB, Fennell DA.

BMC Cancer. 2010 Jul 20;10:380. doi: 10.1186/1471-2407-10-380.

43.

Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer.

Kyula JN, Van Schaeybroeck S, Doherty J, Fenning CS, Longley DB, Johnston PG.

Clin Cancer Res. 2010 Jul 1;16(13):3378-89. doi: 10.1158/1078-0432.CCR-10-0014. Epub 2010 Jun 22.

44.

Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer.

McLornan DP, Barrett HL, Cummins R, McDermott U, McDowell C, Conlon SJ, Coyle VM, Van Schaeybroeck S, Wilson R, Kay EW, Longley DB, Johnston PG.

Clin Cancer Res. 2010 Jul 1;16(13):3442-51. doi: 10.1158/1078-0432.CCR-10-0052. Epub 2010 Jun 22.

45.

Prostate-derived factor--a novel inhibitor of drug-induced cell death in colon cancer cells.

Proutski I, Stevenson L, Allen WL, McCulla A, Boyer J, McLean EG, Longley DB, Johnston PG.

Mol Cancer Ther. 2009 Sep;8(9):2566-74. doi: 10.1158/1535-7163.MCT-09-0158. Epub 2009 Sep 1.

46.

Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing.

Wilson TR, Redmond KM, McLaughlin KM, Crawford N, Gately K, O'Byrne K, Le-Clorrenec C, Holohan C, Fennell DA, Johnston PG, Longley DB.

Cell Death Differ. 2009 Oct;16(10):1352-61. doi: 10.1038/cdd.2009.76. Epub 2009 Jun 19.

47.

Anti-apoptotic mechanisms of drug resistance in cancer.

Wilson TR, Johnston PG, Longley DB.

Curr Cancer Drug Targets. 2009 May;9(3):307-19. Review.

PMID:
19442051
48.

Clinical determinants of response to irinotecan-based therapy derived from cell line models.

Allen WL, Coyle VM, Jithesh PV, Proutski I, Stevenson L, Fenning C, Longley DB, Wilson RH, Gordon M, Lenz HJ, Johnston PG.

Clin Cancer Res. 2008 Oct 15;14(20):6647-55. doi: 10.1158/1078-0432.CCR-08-0452.

49.

Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL.

Van Schaeybroeck S, Kelly DM, Kyula J, Stokesberry S, Fennell DA, Johnston PG, Longley DB.

Cancer Res. 2008 Oct 15;68(20):8312-21. doi: 10.1158/0008-5472.CAN-07-6736.

50.

Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells.

Wilson TR, McEwan M, McLaughlin K, Le Clorennec C, Allen WL, Fennell DA, Johnston PG, Longley DB.

Oncogene. 2009 Jan 8;28(1):63-72. doi: 10.1038/onc.2008.366. Epub 2008 Sep 29.

PMID:
18820704

Supplemental Content

Loading ...
Support Center